nodes	percent_of_prediction	percent_of_DWPC	metapath
Pioglitazone—PPARG—psoriasis	0.41	1	CbGaD
Pioglitazone—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0595	0.137	CbGbCtD
Pioglitazone—CYP2C8—Tazarotene—psoriasis	0.0396	0.0914	CbGbCtD
Pioglitazone—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0347	0.0799	CbGbCtD
Pioglitazone—SLCO1B1—Cyclosporine—psoriasis	0.0263	0.0606	CbGbCtD
Pioglitazone—SLCO1B3—Methotrexate—psoriasis	0.0239	0.055	CbGbCtD
Pioglitazone—CYP2D6—Hydroxyurea—psoriasis	0.0178	0.0411	CbGbCtD
Pioglitazone—CYP2C8—Cholecalciferol—psoriasis	0.0169	0.039	CbGbCtD
Pioglitazone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0147	0.0338	CbGbCtD
Pioglitazone—CYP2C19—Cholecalciferol—psoriasis	0.0142	0.0327	CbGbCtD
Pioglitazone—SLCO1B1—Methotrexate—psoriasis	0.0139	0.0321	CbGbCtD
Pioglitazone—CYP3A4—Calcitriol—psoriasis	0.0133	0.0307	CbGbCtD
Pioglitazone—CYP2C9—Cholecalciferol—psoriasis	0.0118	0.0272	CbGbCtD
Pioglitazone—CYP2C8—Hydrocortisone—psoriasis	0.0118	0.0271	CbGbCtD
Pioglitazone—CYP2C8—Cyclosporine—psoriasis	0.0111	0.0256	CbGbCtD
Pioglitazone—CYP2D6—Cholecalciferol—psoriasis	0.0108	0.0249	CbGbCtD
Pioglitazone—CYP3A4—Methoxsalen—psoriasis	0.0104	0.0239	CbGbCtD
Pioglitazone—CYP2C19—Prednisone—psoriasis	0.00984	0.0227	CbGbCtD
Pioglitazone—CYP2C19—Cyclosporine—psoriasis	0.00933	0.0215	CbGbCtD
Pioglitazone—CYP2C9—Cyclosporine—psoriasis	0.00775	0.0179	CbGbCtD
Pioglitazone—CYP2C8—Dexamethasone—psoriasis	0.00732	0.0169	CbGbCtD
Pioglitazone—CYP2D6—Cyclosporine—psoriasis	0.00709	0.0163	CbGbCtD
Pioglitazone—CYP3A4—Cholecalciferol—psoriasis	0.00686	0.0158	CbGbCtD
Pioglitazone—CYP2C19—Dexamethasone—psoriasis	0.00614	0.0142	CbGbCtD
Pioglitazone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00595	0.0137	CbGbCtD
Pioglitazone—CYP3A4—Triamcinolone—psoriasis	0.00595	0.0137	CbGbCtD
Pioglitazone—CYP2C9—Dexamethasone—psoriasis	0.00511	0.0118	CbGbCtD
Pioglitazone—CYP3A4—Betamethasone—psoriasis	0.0051	0.0118	CbGbCtD
Pioglitazone—CYP3A4—Prednisolone—psoriasis	0.00504	0.0116	CbGbCtD
Pioglitazone—CYP3A4—Hydrocortisone—psoriasis	0.00477	0.011	CbGbCtD
Pioglitazone—CYP3A4—Prednisone—psoriasis	0.00476	0.011	CbGbCtD
Pioglitazone—CYP2D6—Dexamethasone—psoriasis	0.00467	0.0108	CbGbCtD
Pioglitazone—CYP3A4—Cyclosporine—psoriasis	0.00451	0.0104	CbGbCtD
Pioglitazone—CYP3A4—Dexamethasone—psoriasis	0.00297	0.00685	CbGbCtD
Pioglitazone—Rosiglitazone—PPARG—psoriasis	0.00208	1	CrCbGaD
Pioglitazone—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000937	0.0519	CbGpPWpGaD
Pioglitazone—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000837	0.0463	CbGpPWpGaD
Pioglitazone—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000769	0.0426	CbGpPWpGaD
Pioglitazone—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000763	0.0422	CbGpPWpGaD
Pioglitazone—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000718	0.0397	CbGpPWpGaD
Pioglitazone—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000581	0.0321	CbGpPWpGaD
Pioglitazone—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000519	0.0287	CbGpPWpGaD
Pioglitazone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000477	0.0264	CbGpPWpGaD
Pioglitazone—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000473	0.0262	CbGpPWpGaD
Pioglitazone—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000336	0.0186	CbGpPWpGaD
Pioglitazone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000312	0.0173	CbGpPWpGaD
Pioglitazone—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000304	0.0168	CbGpPWpGaD
Pioglitazone—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000303	0.0167	CbGpPWpGaD
Pioglitazone—PPARG—Transcription factor regulation in adipogenesis—LEP—psoriasis	0.000278	0.0154	CbGpPWpGaD
Pioglitazone—PPARG—Differentiation of white and brown adipocyte   —LEP—psoriasis	0.000251	0.0139	CbGpPWpGaD
Pioglitazone—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000245	0.0135	CbGpPWpGaD
Pioglitazone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000241	0.0133	CbGpPWpGaD
Pioglitazone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000238	0.0132	CbGpPWpGaD
Pioglitazone—PPARG—Nuclear Receptors—VDR—psoriasis	0.000224	0.0124	CbGpPWpGaD
Pioglitazone—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000223	0.0124	CbGpPWpGaD
Pioglitazone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000215	0.0119	CbGpPWpGaD
Pioglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000213	0.0118	CbGpPWpGaD
Pioglitazone—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000212	0.0118	CbGpPWpGaD
Pioglitazone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000198	0.011	CbGpPWpGaD
Pioglitazone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000196	0.0109	CbGpPWpGaD
Pioglitazone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000196	0.0108	CbGpPWpGaD
Pioglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000195	0.0108	CbGpPWpGaD
Pioglitazone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000194	0.0107	CbGpPWpGaD
Pioglitazone—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000177	0.0098	CbGpPWpGaD
Pioglitazone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000175	0.00966	CbGpPWpGaD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.00017	0.00942	CbGpPWpGaD
Pioglitazone—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000161	0.0089	CbGpPWpGaD
Pioglitazone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000161	0.00888	CbGpPWpGaD
Pioglitazone—PPARG—PPARA activates gene expression—CARM1—psoriasis	0.00016	0.00887	CbGpPWpGaD
Pioglitazone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000159	0.00881	CbGpPWpGaD
Pioglitazone—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000157	0.00868	CbGpPWpGaD
Pioglitazone—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000145	0.00804	CbGpPWpGaD
Pioglitazone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000129	0.00716	CbGpPWpGaD
Pioglitazone—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000128	0.00711	CbGpPWpGaD
Pioglitazone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000128	0.00707	CbGpPWpGaD
Pioglitazone—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000112	0.00622	CbGpPWpGaD
Pioglitazone—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000108	0.00598	CbGpPWpGaD
Pioglitazone—Vertigo—Mycophenolate mofetil—psoriasis	0.000105	0.000771	CcSEcCtD
Pioglitazone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000105	0.00581	CbGpPWpGaD
Pioglitazone—Erectile dysfunction—Prednisone—psoriasis	0.000105	0.000769	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000105	0.000767	CcSEcCtD
Pioglitazone—Fatigue—Mycophenolic acid—psoriasis	0.000104	0.000765	CcSEcCtD
Pioglitazone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000104	0.00575	CbGpPWpGaD
Pioglitazone—Asthenia—Hydroxyurea—psoriasis	0.000104	0.000761	CcSEcCtD
Pioglitazone—Weight increased—Prednisone—psoriasis	0.000104	0.00076	CcSEcCtD
Pioglitazone—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.000104	0.00573	CbGpPWpGaD
Pioglitazone—Hypertension—Cyclosporine—psoriasis	0.000104	0.00076	CcSEcCtD
Pioglitazone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000104	0.00573	CbGpPWpGaD
Pioglitazone—Weight decreased—Prednisone—psoriasis	0.000103	0.000756	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000103	0.00569	CbGpPWpGaD
Pioglitazone—Hyperglycaemia—Prednisone—psoriasis	0.000103	0.000753	CcSEcCtD
Pioglitazone—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	0.000102	0.00567	CbGpPWpGaD
Pioglitazone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000102	0.00567	CbGpPWpGaD
Pioglitazone—Myalgia—Cyclosporine—psoriasis	0.000102	0.000749	CcSEcCtD
Pioglitazone—Chest pain—Cyclosporine—psoriasis	0.000102	0.000749	CcSEcCtD
Pioglitazone—Arthralgia—Cyclosporine—psoriasis	0.000102	0.000749	CcSEcCtD
Pioglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000102	0.00564	CbGpPWpGaD
Pioglitazone—Liver function test abnormal—Methotrexate—psoriasis	0.000102	0.000746	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000102	0.000744	CcSEcCtD
Pioglitazone—Ill-defined disorder—Prednisolone—psoriasis	0.000101	0.000743	CcSEcCtD
Pioglitazone—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000101	0.0056	CbGpPWpGaD
Pioglitazone—Hypertension—Mycophenolate mofetil—psoriasis	0.000101	0.000741	CcSEcCtD
Pioglitazone—Discomfort—Cyclosporine—psoriasis	0.000101	0.00074	CcSEcCtD
Pioglitazone—Visual impairment—Dexamethasone—psoriasis	0.000101	0.00074	CcSEcCtD
Pioglitazone—Visual impairment—Betamethasone—psoriasis	0.000101	0.00074	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Prednisone—psoriasis	0.0001	0.000734	CcSEcCtD
Pioglitazone—Angioedema—Prednisolone—psoriasis	9.98e-05	0.000732	CcSEcCtD
Pioglitazone—Feeling abnormal—Mycophenolic acid—psoriasis	9.98e-05	0.000732	CcSEcCtD
Pioglitazone—Chest pain—Mycophenolate mofetil—psoriasis	9.97e-05	0.000731	CcSEcCtD
Pioglitazone—Arthralgia—Mycophenolate mofetil—psoriasis	9.97e-05	0.000731	CcSEcCtD
Pioglitazone—Myalgia—Mycophenolate mofetil—psoriasis	9.97e-05	0.000731	CcSEcCtD
Pioglitazone—Myocardial infarction—Prednisone—psoriasis	9.96e-05	0.00073	CcSEcCtD
Pioglitazone—Breast disorder—Methotrexate—psoriasis	9.95e-05	0.00073	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	9.9e-05	0.000726	CcSEcCtD
Pioglitazone—Ill-defined disorder—Hydrocortisone—psoriasis	9.9e-05	0.000726	CcSEcCtD
Pioglitazone—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	9.9e-05	0.00548	CbGpPWpGaD
Pioglitazone—Diarrhoea—Hydroxyurea—psoriasis	9.89e-05	0.000725	CcSEcCtD
Pioglitazone—Malaise—Prednisolone—psoriasis	9.85e-05	0.000722	CcSEcCtD
Pioglitazone—Discomfort—Mycophenolate mofetil—psoriasis	9.85e-05	0.000722	CcSEcCtD
Pioglitazone—Vertigo—Prednisolone—psoriasis	9.81e-05	0.00072	CcSEcCtD
Pioglitazone—Anaphylactic shock—Cyclosporine—psoriasis	9.8e-05	0.000718	CcSEcCtD
Pioglitazone—Oedema—Cyclosporine—psoriasis	9.8e-05	0.000718	CcSEcCtD
Pioglitazone—Eye disorder—Dexamethasone—psoriasis	9.79e-05	0.000717	CcSEcCtD
Pioglitazone—Eye disorder—Betamethasone—psoriasis	9.79e-05	0.000717	CcSEcCtD
Pioglitazone—Angioedema—Hydrocortisone—psoriasis	9.75e-05	0.000715	CcSEcCtD
Pioglitazone—Infection—Cyclosporine—psoriasis	9.73e-05	0.000714	CcSEcCtD
Pioglitazone—Back pain—Triamcinolone—psoriasis	9.72e-05	0.000712	CcSEcCtD
Pioglitazone—Malaise—Hydrocortisone—psoriasis	9.62e-05	0.000705	CcSEcCtD
Pioglitazone—Nervous system disorder—Cyclosporine—psoriasis	9.61e-05	0.000704	CcSEcCtD
Pioglitazone—Vertigo—Hydrocortisone—psoriasis	9.59e-05	0.000703	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	9.57e-05	0.00529	CbGpPWpGaD
Pioglitazone—Dizziness—Hydroxyurea—psoriasis	9.56e-05	0.000701	CcSEcCtD
Pioglitazone—Oedema—Mycophenolate mofetil—psoriasis	9.56e-05	0.000701	CcSEcCtD
Pioglitazone—Anaphylactic shock—Mycophenolate mofetil—psoriasis	9.56e-05	0.000701	CcSEcCtD
Pioglitazone—Skin disorder—Cyclosporine—psoriasis	9.52e-05	0.000698	CcSEcCtD
Pioglitazone—Infection—Mycophenolate mofetil—psoriasis	9.5e-05	0.000696	CcSEcCtD
Pioglitazone—Hyperhidrosis—Cyclosporine—psoriasis	9.47e-05	0.000694	CcSEcCtD
Pioglitazone—Hypertension—Prednisolone—psoriasis	9.43e-05	0.000691	CcSEcCtD
Pioglitazone—Nervous system disorder—Mycophenolate mofetil—psoriasis	9.37e-05	0.000687	CcSEcCtD
Pioglitazone—Ill-defined disorder—Triamcinolone—psoriasis	9.32e-05	0.000683	CcSEcCtD
Pioglitazone—Skin disorder—Mycophenolate mofetil—psoriasis	9.28e-05	0.000681	CcSEcCtD
Pioglitazone—CYP2C19—Biological oxidations—CYP2S1—psoriasis	9.27e-05	0.00513	CbGpPWpGaD
Pioglitazone—Hyperhidrosis—Mycophenolate mofetil—psoriasis	9.24e-05	0.000677	CcSEcCtD
Pioglitazone—Hypertension—Hydrocortisone—psoriasis	9.21e-05	0.000675	CcSEcCtD
Pioglitazone—Discomfort—Prednisolone—psoriasis	9.19e-05	0.000674	CcSEcCtD
Pioglitazone—Angioedema—Triamcinolone—psoriasis	9.18e-05	0.000673	CcSEcCtD
Pioglitazone—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	9.15e-05	0.00506	CbGpPWpGaD
Pioglitazone—PPARG—Adipogenesis—SOCS1—psoriasis	9.08e-05	0.00503	CbGpPWpGaD
Pioglitazone—Myalgia—Hydrocortisone—psoriasis	9.08e-05	0.000666	CcSEcCtD
Pioglitazone—Malaise—Triamcinolone—psoriasis	9.06e-05	0.000664	CcSEcCtD
Pioglitazone—Headache—Hydroxyurea—psoriasis	9.06e-05	0.000664	CcSEcCtD
Pioglitazone—Vertigo—Triamcinolone—psoriasis	9.03e-05	0.000662	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	9.02e-05	0.000661	CcSEcCtD
Pioglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.02e-05	0.00499	CbGpPWpGaD
Pioglitazone—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	8.99e-05	0.00497	CbGpPWpGaD
Pioglitazone—Discomfort—Hydrocortisone—psoriasis	8.97e-05	0.000658	CcSEcCtD
Pioglitazone—Connective tissue disorder—Prednisone—psoriasis	8.96e-05	0.000657	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Cyclosporine—psoriasis	8.93e-05	0.000654	CcSEcCtD
Pioglitazone—Anaphylactic shock—Prednisolone—psoriasis	8.92e-05	0.000654	CcSEcCtD
Pioglitazone—Oedema—Prednisolone—psoriasis	8.92e-05	0.000654	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	8.89e-05	0.00492	CbGpPWpGaD
Pioglitazone—Insomnia—Cyclosporine—psoriasis	8.86e-05	0.00065	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Methotrexate—psoriasis	8.85e-05	0.000649	CcSEcCtD
Pioglitazone—Erectile dysfunction—Methotrexate—psoriasis	8.77e-05	0.000643	CcSEcCtD
Pioglitazone—Dyspnoea—Cyclosporine—psoriasis	8.73e-05	0.00064	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	8.71e-05	0.000638	CcSEcCtD
Pioglitazone—Anaphylactic shock—Hydrocortisone—psoriasis	8.71e-05	0.000638	CcSEcCtD
Pioglitazone—Oedema—Hydrocortisone—psoriasis	8.71e-05	0.000638	CcSEcCtD
Pioglitazone—Asthenia—Mycophenolic acid—psoriasis	8.69e-05	0.000637	CcSEcCtD
Pioglitazone—Hypertension—Triamcinolone—psoriasis	8.67e-05	0.000636	CcSEcCtD
Pioglitazone—Infection—Hydrocortisone—psoriasis	8.65e-05	0.000634	CcSEcCtD
Pioglitazone—Insomnia—Mycophenolate mofetil—psoriasis	8.64e-05	0.000634	CcSEcCtD
Pioglitazone—Hyperhidrosis—Prednisolone—psoriasis	8.62e-05	0.000632	CcSEcCtD
Pioglitazone—Myalgia—Triamcinolone—psoriasis	8.55e-05	0.000627	CcSEcCtD
Pioglitazone—Nervous system disorder—Hydrocortisone—psoriasis	8.54e-05	0.000626	CcSEcCtD
Pioglitazone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	8.53e-05	0.00472	CbGpPWpGaD
Pioglitazone—Eye disorder—Prednisone—psoriasis	8.52e-05	0.000625	CcSEcCtD
Pioglitazone—Dyspnoea—Mycophenolate mofetil—psoriasis	8.52e-05	0.000625	CcSEcCtD
Pioglitazone—Infestation—Methotrexate—psoriasis	8.49e-05	0.000622	CcSEcCtD
Pioglitazone—Infestation NOS—Methotrexate—psoriasis	8.49e-05	0.000622	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Cyclosporine—psoriasis	8.46e-05	0.00062	CcSEcCtD
Pioglitazone—Skin disorder—Hydrocortisone—psoriasis	8.46e-05	0.00062	CcSEcCtD
Pioglitazone—Ill-defined disorder—Dexamethasone—psoriasis	8.46e-05	0.00062	CcSEcCtD
Pioglitazone—Ill-defined disorder—Betamethasone—psoriasis	8.46e-05	0.00062	CcSEcCtD
Pioglitazone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	8.45e-05	0.00468	CbGpPWpGaD
Pioglitazone—Discomfort—Triamcinolone—psoriasis	8.45e-05	0.00062	CcSEcCtD
Pioglitazone—Fatigue—Cyclosporine—psoriasis	8.45e-05	0.000619	CcSEcCtD
Pioglitazone—Hyperhidrosis—Hydrocortisone—psoriasis	8.42e-05	0.000617	CcSEcCtD
Pioglitazone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	8.41e-05	0.00465	CbGpPWpGaD
Pioglitazone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	8.34e-05	0.00461	CbGpPWpGaD
Pioglitazone—Angioedema—Dexamethasone—psoriasis	8.33e-05	0.000611	CcSEcCtD
Pioglitazone—Angioedema—Betamethasone—psoriasis	8.33e-05	0.000611	CcSEcCtD
Pioglitazone—Diarrhoea—Mycophenolic acid—psoriasis	8.29e-05	0.000608	CcSEcCtD
Pioglitazone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	8.27e-05	0.00457	CbGpPWpGaD
Pioglitazone—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	8.26e-05	0.00457	CbGpPWpGaD
Pioglitazone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.25e-05	0.000605	CcSEcCtD
Pioglitazone—Immune system disorder—Prednisone—psoriasis	8.24e-05	0.000604	CcSEcCtD
Pioglitazone—Malaise—Dexamethasone—psoriasis	8.22e-05	0.000603	CcSEcCtD
Pioglitazone—Malaise—Betamethasone—psoriasis	8.22e-05	0.000603	CcSEcCtD
Pioglitazone—Anaphylactic shock—Triamcinolone—psoriasis	8.2e-05	0.000601	CcSEcCtD
Pioglitazone—Oedema—Triamcinolone—psoriasis	8.2e-05	0.000601	CcSEcCtD
Pioglitazone—Vertigo—Dexamethasone—psoriasis	8.19e-05	0.0006	CcSEcCtD
Pioglitazone—Vertigo—Betamethasone—psoriasis	8.19e-05	0.0006	CcSEcCtD
Pioglitazone—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	8.16e-05	0.00452	CbGpPWpGaD
Pioglitazone—Infection—Triamcinolone—psoriasis	8.15e-05	0.000597	CcSEcCtD
Pioglitazone—Sweating—Methotrexate—psoriasis	8.14e-05	0.000597	CcSEcCtD
Pioglitazone—Haematuria—Methotrexate—psoriasis	8.09e-05	0.000593	CcSEcCtD
Pioglitazone—Feeling abnormal—Cyclosporine—psoriasis	8.07e-05	0.000592	CcSEcCtD
Pioglitazone—Insomnia—Prednisolone—psoriasis	8.06e-05	0.000591	CcSEcCtD
Pioglitazone—Dizziness—Mycophenolic acid—psoriasis	8.01e-05	0.000587	CcSEcCtD
Pioglitazone—Malnutrition—Prednisone—psoriasis	7.94e-05	0.000582	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.93e-05	0.000582	CcSEcCtD
Pioglitazone—Hyperhidrosis—Triamcinolone—psoriasis	7.93e-05	0.000581	CcSEcCtD
Pioglitazone—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.88e-05	0.000577	CcSEcCtD
Pioglitazone—Insomnia—Hydrocortisone—psoriasis	7.88e-05	0.000577	CcSEcCtD
Pioglitazone—Hypertension—Dexamethasone—psoriasis	7.87e-05	0.000577	CcSEcCtD
Pioglitazone—Hypertension—Betamethasone—psoriasis	7.87e-05	0.000577	CcSEcCtD
Pioglitazone—PPARG—Gene Expression—TARS—psoriasis	7.84e-05	0.00433	CbGpPWpGaD
Pioglitazone—Urticaria—Cyclosporine—psoriasis	7.78e-05	0.000571	CcSEcCtD
Pioglitazone—Myalgia—Dexamethasone—psoriasis	7.76e-05	0.000569	CcSEcCtD
Pioglitazone—Myalgia—Betamethasone—psoriasis	7.76e-05	0.000569	CcSEcCtD
Pioglitazone—Discomfort—Dexamethasone—psoriasis	7.67e-05	0.000562	CcSEcCtD
Pioglitazone—Discomfort—Betamethasone—psoriasis	7.67e-05	0.000562	CcSEcCtD
Pioglitazone—Hepatitis—Methotrexate—psoriasis	7.62e-05	0.000559	CcSEcCtD
Pioglitazone—Urticaria—Mycophenolate mofetil—psoriasis	7.59e-05	0.000557	CcSEcCtD
Pioglitazone—Headache—Mycophenolic acid—psoriasis	7.59e-05	0.000556	CcSEcCtD
Pioglitazone—Pharyngitis—Methotrexate—psoriasis	7.56e-05	0.000555	CcSEcCtD
Pioglitazone—Urinary tract disorder—Methotrexate—psoriasis	7.53e-05	0.000552	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.52e-05	0.000551	CcSEcCtD
Pioglitazone—Fatigue—Hydrocortisone—psoriasis	7.51e-05	0.00055	CcSEcCtD
Pioglitazone—Urethral disorder—Methotrexate—psoriasis	7.47e-05	0.000548	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.47e-05	0.000548	CcSEcCtD
Pioglitazone—Oedema—Dexamethasone—psoriasis	7.44e-05	0.000545	CcSEcCtD
Pioglitazone—Anaphylactic shock—Betamethasone—psoriasis	7.44e-05	0.000545	CcSEcCtD
Pioglitazone—Anaphylactic shock—Dexamethasone—psoriasis	7.44e-05	0.000545	CcSEcCtD
Pioglitazone—Oedema—Betamethasone—psoriasis	7.44e-05	0.000545	CcSEcCtD
Pioglitazone—Insomnia—Triamcinolone—psoriasis	7.42e-05	0.000544	CcSEcCtD
Pioglitazone—Infection—Dexamethasone—psoriasis	7.39e-05	0.000542	CcSEcCtD
Pioglitazone—Infection—Betamethasone—psoriasis	7.39e-05	0.000542	CcSEcCtD
Pioglitazone—Ill-defined disorder—Prednisone—psoriasis	7.37e-05	0.00054	CcSEcCtD
Pioglitazone—Feeling abnormal—Prednisolone—psoriasis	7.35e-05	0.000539	CcSEcCtD
Pioglitazone—Visual impairment—Methotrexate—psoriasis	7.34e-05	0.000538	CcSEcCtD
Pioglitazone—Anaemia—Prednisone—psoriasis	7.34e-05	0.000538	CcSEcCtD
Pioglitazone—Dyspnoea—Triamcinolone—psoriasis	7.31e-05	0.000536	CcSEcCtD
Pioglitazone—Nervous system disorder—Betamethasone—psoriasis	7.3e-05	0.000535	CcSEcCtD
Pioglitazone—Nervous system disorder—Dexamethasone—psoriasis	7.3e-05	0.000535	CcSEcCtD
Pioglitazone—Angioedema—Prednisone—psoriasis	7.25e-05	0.000532	CcSEcCtD
Pioglitazone—Hypersensitivity—Cyclosporine—psoriasis	7.22e-05	0.000529	CcSEcCtD
Pioglitazone—Hyperhidrosis—Dexamethasone—psoriasis	7.19e-05	0.000527	CcSEcCtD
Pioglitazone—Hyperhidrosis—Betamethasone—psoriasis	7.19e-05	0.000527	CcSEcCtD
Pioglitazone—Feeling abnormal—Hydrocortisone—psoriasis	7.18e-05	0.000526	CcSEcCtD
Pioglitazone—Malaise—Prednisone—psoriasis	7.16e-05	0.000525	CcSEcCtD
Pioglitazone—Vertigo—Prednisone—psoriasis	7.13e-05	0.000523	CcSEcCtD
Pioglitazone—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	7.12e-05	0.00394	CbGpPWpGaD
Pioglitazone—Eye disorder—Methotrexate—psoriasis	7.12e-05	0.000522	CcSEcCtD
Pioglitazone—Urticaria—Prednisolone—psoriasis	7.08e-05	0.000519	CcSEcCtD
Pioglitazone—Cardiac disorder—Methotrexate—psoriasis	7.07e-05	0.000519	CcSEcCtD
Pioglitazone—Fatigue—Triamcinolone—psoriasis	7.07e-05	0.000518	CcSEcCtD
Pioglitazone—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.04e-05	0.000516	CcSEcCtD
Pioglitazone—Asthenia—Cyclosporine—psoriasis	7.03e-05	0.000515	CcSEcCtD
Pioglitazone—Urticaria—Hydrocortisone—psoriasis	6.92e-05	0.000507	CcSEcCtD
Pioglitazone—Immune system disorder—Methotrexate—psoriasis	6.88e-05	0.000505	CcSEcCtD
Pioglitazone—Mediastinal disorder—Methotrexate—psoriasis	6.87e-05	0.000504	CcSEcCtD
Pioglitazone—Asthenia—Mycophenolate mofetil—psoriasis	6.86e-05	0.000503	CcSEcCtD
Pioglitazone—Hypertension—Prednisone—psoriasis	6.85e-05	0.000502	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.78e-05	0.000497	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Betamethasone—psoriasis	6.78e-05	0.000497	CcSEcCtD
Pioglitazone—Myalgia—Prednisone—psoriasis	6.76e-05	0.000495	CcSEcCtD
Pioglitazone—Arthralgia—Prednisone—psoriasis	6.76e-05	0.000495	CcSEcCtD
Pioglitazone—Feeling abnormal—Triamcinolone—psoriasis	6.76e-05	0.000495	CcSEcCtD
Pioglitazone—Insomnia—Betamethasone—psoriasis	6.73e-05	0.000493	CcSEcCtD
Pioglitazone—Insomnia—Dexamethasone—psoriasis	6.73e-05	0.000493	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.71e-05	0.000492	CcSEcCtD
Pioglitazone—Diarrhoea—Cyclosporine—psoriasis	6.7e-05	0.000491	CcSEcCtD
Pioglitazone—PPARG—Adipogenesis—LEP—psoriasis	6.7e-05	0.00371	CbGpPWpGaD
Pioglitazone—Discomfort—Prednisone—psoriasis	6.68e-05	0.00049	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	6.66e-05	0.00368	CbGpPWpGaD
Pioglitazone—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	6.65e-05	0.00368	CbGpPWpGaD
Pioglitazone—Malnutrition—Methotrexate—psoriasis	6.63e-05	0.000486	CcSEcCtD
Pioglitazone—Hypersensitivity—Prednisolone—psoriasis	6.57e-05	0.000482	CcSEcCtD
Pioglitazone—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	6.56e-05	0.00363	CbGpPWpGaD
Pioglitazone—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	6.54e-05	0.00362	CbGpPWpGaD
Pioglitazone—Diarrhoea—Mycophenolate mofetil—psoriasis	6.54e-05	0.000479	CcSEcCtD
Pioglitazone—Urticaria—Triamcinolone—psoriasis	6.51e-05	0.000478	CcSEcCtD
Pioglitazone—Dizziness—Cyclosporine—psoriasis	6.48e-05	0.000475	CcSEcCtD
Pioglitazone—Anaphylactic shock—Prednisone—psoriasis	6.48e-05	0.000475	CcSEcCtD
Pioglitazone—Oedema—Prednisone—psoriasis	6.48e-05	0.000475	CcSEcCtD
Pioglitazone—Infection—Prednisone—psoriasis	6.44e-05	0.000472	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Betamethasone—psoriasis	6.42e-05	0.000471	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Dexamethasone—psoriasis	6.42e-05	0.000471	CcSEcCtD
Pioglitazone—Back pain—Methotrexate—psoriasis	6.42e-05	0.00047	CcSEcCtD
Pioglitazone—Hypersensitivity—Hydrocortisone—psoriasis	6.42e-05	0.00047	CcSEcCtD
Pioglitazone—Fatigue—Dexamethasone—psoriasis	6.41e-05	0.00047	CcSEcCtD
Pioglitazone—Fatigue—Betamethasone—psoriasis	6.41e-05	0.00047	CcSEcCtD
Pioglitazone—Nervous system disorder—Prednisone—psoriasis	6.35e-05	0.000466	CcSEcCtD
Pioglitazone—Dizziness—Mycophenolate mofetil—psoriasis	6.32e-05	0.000463	CcSEcCtD
Pioglitazone—Skin disorder—Prednisone—psoriasis	6.29e-05	0.000461	CcSEcCtD
Pioglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.29e-05	0.00348	CbGpPWpGaD
Pioglitazone—Hyperhidrosis—Prednisone—psoriasis	6.26e-05	0.000459	CcSEcCtD
Pioglitazone—Asthenia—Hydrocortisone—psoriasis	6.25e-05	0.000458	CcSEcCtD
Pioglitazone—Ill-defined disorder—Methotrexate—psoriasis	6.16e-05	0.000451	CcSEcCtD
Pioglitazone—Headache—Cyclosporine—psoriasis	6.14e-05	0.00045	CcSEcCtD
Pioglitazone—Anaemia—Methotrexate—psoriasis	6.13e-05	0.00045	CcSEcCtD
Pioglitazone—Feeling abnormal—Dexamethasone—psoriasis	6.13e-05	0.000449	CcSEcCtD
Pioglitazone—Feeling abnormal—Betamethasone—psoriasis	6.13e-05	0.000449	CcSEcCtD
Pioglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	6.06e-05	0.00335	CbGpPWpGaD
Pioglitazone—Hypersensitivity—Triamcinolone—psoriasis	6.04e-05	0.000443	CcSEcCtD
Pioglitazone—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	6.03e-05	0.00333	CbGpPWpGaD
Pioglitazone—Headache—Mycophenolate mofetil—psoriasis	5.99e-05	0.000439	CcSEcCtD
Pioglitazone—Malaise—Methotrexate—psoriasis	5.98e-05	0.000439	CcSEcCtD
Pioglitazone—Vertigo—Methotrexate—psoriasis	5.96e-05	0.000437	CcSEcCtD
Pioglitazone—Diarrhoea—Hydrocortisone—psoriasis	5.96e-05	0.000437	CcSEcCtD
Pioglitazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.95e-05	0.00329	CbGpPWpGaD
Pioglitazone—Urticaria—Dexamethasone—psoriasis	5.91e-05	0.000433	CcSEcCtD
Pioglitazone—Urticaria—Betamethasone—psoriasis	5.91e-05	0.000433	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Prednisone—psoriasis	5.9e-05	0.000433	CcSEcCtD
Pioglitazone—Dizziness—Prednisolone—psoriasis	5.9e-05	0.000432	CcSEcCtD
Pioglitazone—Asthenia—Triamcinolone—psoriasis	5.88e-05	0.000431	CcSEcCtD
Pioglitazone—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	5.88e-05	0.00325	CbGpPWpGaD
Pioglitazone—Insomnia—Prednisone—psoriasis	5.86e-05	0.00043	CcSEcCtD
Pioglitazone—Dizziness—Hydrocortisone—psoriasis	5.76e-05	0.000422	CcSEcCtD
Pioglitazone—Myalgia—Methotrexate—psoriasis	5.65e-05	0.000414	CcSEcCtD
Pioglitazone—Chest pain—Methotrexate—psoriasis	5.65e-05	0.000414	CcSEcCtD
Pioglitazone—Arthralgia—Methotrexate—psoriasis	5.65e-05	0.000414	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.61e-05	0.000411	CcSEcCtD
Pioglitazone—Fatigue—Prednisone—psoriasis	5.59e-05	0.00041	CcSEcCtD
Pioglitazone—Headache—Prednisolone—psoriasis	5.59e-05	0.000409	CcSEcCtD
Pioglitazone—Discomfort—Methotrexate—psoriasis	5.58e-05	0.000409	CcSEcCtD
Pioglitazone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.58e-05	0.00308	CbGpPWpGaD
Pioglitazone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.5e-05	0.00304	CbGpPWpGaD
Pioglitazone—Headache—Hydrocortisone—psoriasis	5.45e-05	0.0004	CcSEcCtD
Pioglitazone—Dizziness—Triamcinolone—psoriasis	5.42e-05	0.000397	CcSEcCtD
Pioglitazone—Anaphylactic shock—Methotrexate—psoriasis	5.41e-05	0.000397	CcSEcCtD
Pioglitazone—SLCO1B3—Metabolism—NDUFA5—psoriasis	5.41e-05	0.00299	CbGpPWpGaD
Pioglitazone—Infection—Methotrexate—psoriasis	5.38e-05	0.000394	CcSEcCtD
Pioglitazone—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	5.35e-05	0.00296	CbGpPWpGaD
Pioglitazone—Feeling abnormal—Prednisone—psoriasis	5.34e-05	0.000391	CcSEcCtD
Pioglitazone—Asthenia—Dexamethasone—psoriasis	5.34e-05	0.000391	CcSEcCtD
Pioglitazone—Asthenia—Betamethasone—psoriasis	5.34e-05	0.000391	CcSEcCtD
Pioglitazone—Nervous system disorder—Methotrexate—psoriasis	5.31e-05	0.000389	CcSEcCtD
Pioglitazone—Skin disorder—Methotrexate—psoriasis	5.26e-05	0.000386	CcSEcCtD
Pioglitazone—Hyperhidrosis—Methotrexate—psoriasis	5.23e-05	0.000384	CcSEcCtD
Pioglitazone—Urticaria—Prednisone—psoriasis	5.15e-05	0.000377	CcSEcCtD
Pioglitazone—Headache—Triamcinolone—psoriasis	5.14e-05	0.000377	CcSEcCtD
Pioglitazone—PPARG—Generic Transcription Pathway—CARM1—psoriasis	5.12e-05	0.00283	CbGpPWpGaD
Pioglitazone—Diarrhoea—Betamethasone—psoriasis	5.09e-05	0.000373	CcSEcCtD
Pioglitazone—Diarrhoea—Dexamethasone—psoriasis	5.09e-05	0.000373	CcSEcCtD
Pioglitazone—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	5.09e-05	0.00281	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.05e-05	0.00279	CbGpPWpGaD
Pioglitazone—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	5.03e-05	0.00278	CbGpPWpGaD
Pioglitazone—Musculoskeletal discomfort—Methotrexate—psoriasis	4.93e-05	0.000362	CcSEcCtD
Pioglitazone—Dizziness—Betamethasone—psoriasis	4.92e-05	0.000361	CcSEcCtD
Pioglitazone—Dizziness—Dexamethasone—psoriasis	4.92e-05	0.000361	CcSEcCtD
Pioglitazone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4.92e-05	0.00272	CbGpPWpGaD
Pioglitazone—Insomnia—Methotrexate—psoriasis	4.9e-05	0.000359	CcSEcCtD
Pioglitazone—Dyspnoea—Methotrexate—psoriasis	4.83e-05	0.000354	CcSEcCtD
Pioglitazone—PPARG—Developmental Biology—CARM1—psoriasis	4.82e-05	0.00267	CbGpPWpGaD
Pioglitazone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.81e-05	0.00266	CbGpPWpGaD
Pioglitazone—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	4.8e-05	0.00265	CbGpPWpGaD
Pioglitazone—Hypersensitivity—Prednisone—psoriasis	4.77e-05	0.00035	CcSEcCtD
Pioglitazone—PPARG—Circadian rythm related genes—LEP—psoriasis	4.73e-05	0.00262	CbGpPWpGaD
Pioglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	4.71e-05	0.00261	CbGpPWpGaD
Pioglitazone—Gastrointestinal disorder—Methotrexate—psoriasis	4.67e-05	0.000343	CcSEcCtD
Pioglitazone—Fatigue—Methotrexate—psoriasis	4.67e-05	0.000342	CcSEcCtD
Pioglitazone—Headache—Betamethasone—psoriasis	4.66e-05	0.000342	CcSEcCtD
Pioglitazone—Headache—Dexamethasone—psoriasis	4.66e-05	0.000342	CcSEcCtD
Pioglitazone—Asthenia—Prednisone—psoriasis	4.65e-05	0.000341	CcSEcCtD
Pioglitazone—PPARG—Metabolism—NDUFA5—psoriasis	4.62e-05	0.00255	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—CYP2S1—psoriasis	4.6e-05	0.00255	CbGpPWpGaD
Pioglitazone—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	4.59e-05	0.00254	CbGpPWpGaD
Pioglitazone—Feeling abnormal—Methotrexate—psoriasis	4.46e-05	0.000327	CcSEcCtD
Pioglitazone—Diarrhoea—Prednisone—psoriasis	4.43e-05	0.000325	CcSEcCtD
Pioglitazone—PPARG—Circadian rythm related genes—NOS2—psoriasis	4.41e-05	0.00244	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.31e-05	0.00238	CbGpPWpGaD
Pioglitazone—Urticaria—Methotrexate—psoriasis	4.3e-05	0.000315	CcSEcCtD
Pioglitazone—Dizziness—Prednisone—psoriasis	4.28e-05	0.000314	CcSEcCtD
Pioglitazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.15e-05	0.00229	CbGpPWpGaD
Pioglitazone—Headache—Prednisone—psoriasis	4.06e-05	0.000298	CcSEcCtD
Pioglitazone—Hypersensitivity—Methotrexate—psoriasis	3.99e-05	0.000292	CcSEcCtD
Pioglitazone—PPARG—Metabolism—CYP2S1—psoriasis	3.93e-05	0.00217	CbGpPWpGaD
Pioglitazone—Asthenia—Methotrexate—psoriasis	3.88e-05	0.000285	CcSEcCtD
Pioglitazone—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.82e-05	0.00211	CbGpPWpGaD
Pioglitazone—Diarrhoea—Methotrexate—psoriasis	3.7e-05	0.000272	CcSEcCtD
Pioglitazone—SLCO1B1—Metabolism—NDUFA5—psoriasis	3.64e-05	0.00201	CbGpPWpGaD
Pioglitazone—PPARG—Adipogenesis—STAT3—psoriasis	3.58e-05	0.00198	CbGpPWpGaD
Pioglitazone—Dizziness—Methotrexate—psoriasis	3.58e-05	0.000262	CcSEcCtD
Pioglitazone—Headache—Methotrexate—psoriasis	3.39e-05	0.000249	CcSEcCtD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.39e-05	0.00188	CbGpPWpGaD
Pioglitazone—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	3.38e-05	0.00187	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—NDUFA5—psoriasis	3.23e-05	0.00179	CbGpPWpGaD
Pioglitazone—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	3.22e-05	0.00178	CbGpPWpGaD
Pioglitazone—PPARG—Adipogenesis—TNF—psoriasis	3.1e-05	0.00172	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—CYP2S1—psoriasis	3.09e-05	0.00171	CbGpPWpGaD
Pioglitazone—PPARG—Generic Transcription Pathway—VDR—psoriasis	3.06e-05	0.00169	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.02e-05	0.00167	CbGpPWpGaD
Pioglitazone—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	2.97e-05	0.00164	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—JUN—psoriasis	2.92e-05	0.00162	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—CYP2S1—psoriasis	2.75e-05	0.00152	CbGpPWpGaD
Pioglitazone—PPARG—Adipogenesis—IL6—psoriasis	2.5e-05	0.00138	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—CARM1—psoriasis	2.47e-05	0.00136	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.41e-05	0.00133	CbGpPWpGaD
Pioglitazone—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.4e-05	0.00133	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—LEP—psoriasis	2.3e-05	0.00127	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—CARM1—psoriasis	2.25e-05	0.00124	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.1e-05	0.00116	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—NDUFA5—psoriasis	2.09e-05	0.00116	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.06e-05	0.00114	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.95e-05	0.00108	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—TP53—psoriasis	1.93e-05	0.00107	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—CARM1—psoriasis	1.92e-05	0.00106	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NDUFA5—psoriasis	1.86e-05	0.00103	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—CYP2S1—psoriasis	1.78e-05	0.000983	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—IL6—psoriasis	1.77e-05	0.000977	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—TYK2—psoriasis	1.76e-05	0.000973	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.74e-05	0.000962	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—NDUFA5—psoriasis	1.72e-05	0.000949	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NDUFA5—psoriasis	1.7e-05	0.000941	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.62e-05	0.000896	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—CYP2S1—psoriasis	1.59e-05	0.000877	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.59e-05	0.000877	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—CARM1—psoriasis	1.51e-05	0.000835	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—VDR—psoriasis	1.47e-05	0.000815	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.46e-05	0.000807	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.45e-05	0.0008	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.44e-05	0.000797	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.41e-05	0.000781	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—CAT—psoriasis	1.38e-05	0.000765	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—NFKB1—psoriasis	1.37e-05	0.000758	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—CARM1—psoriasis	1.34e-05	0.000743	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.26e-05	0.000695	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—VEGFA—psoriasis	1.24e-05	0.000688	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—STAT3—psoriasis	1.23e-05	0.000681	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—CAT—psoriasis	1.18e-05	0.000652	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.12e-05	0.00062	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—APOE—psoriasis	1.07e-05	0.000594	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—TNF—psoriasis	1.07e-05	0.00059	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—CYP2S1—psoriasis	9.54e-06	0.000528	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—PPARG—psoriasis	9.35e-06	0.000518	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.31e-06	0.000515	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—CAT—psoriasis	9.29e-06	0.000514	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—APOE—psoriasis	9.16e-06	0.000507	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—CARM1—psoriasis	8.68e-06	0.00048	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—IL6—psoriasis	8.6e-06	0.000476	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.31e-06	0.00046	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—CAT—psoriasis	8.26e-06	0.000457	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.11e-06	0.000449	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—CARM1—psoriasis	7.74e-06	0.000428	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.58e-06	0.000419	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.24e-06	0.0004	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—APOE—psoriasis	7.22e-06	0.000399	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—CARM1—psoriasis	7.12e-06	0.000394	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—CARM1—psoriasis	7.06e-06	0.000391	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.6e-06	0.000365	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—APOE—psoriasis	6.42e-06	0.000355	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—PPARG—psoriasis	6.29e-06	0.000348	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—PPARG—psoriasis	5.59e-06	0.000309	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—CAT—psoriasis	5.34e-06	0.000295	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—CAT—psoriasis	4.76e-06	0.000264	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—CARM1—psoriasis	4.66e-06	0.000258	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—CAT—psoriasis	4.38e-06	0.000242	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—CAT—psoriasis	4.34e-06	0.00024	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—APOE—psoriasis	4.15e-06	0.000229	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—APOE—psoriasis	3.7e-06	0.000205	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—PPARG—psoriasis	3.61e-06	0.0002	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—APOE—psoriasis	3.4e-06	0.000188	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—APOE—psoriasis	3.37e-06	0.000187	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—PPARG—psoriasis	3.22e-06	0.000178	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—PPARG—psoriasis	2.96e-06	0.000164	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—PPARG—psoriasis	2.94e-06	0.000163	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—CAT—psoriasis	2.86e-06	0.000158	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—APOE—psoriasis	2.23e-06	0.000123	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—PPARG—psoriasis	1.94e-06	0.000107	CbGpPWpGaD
